Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Alfredo Pontecorvi, Gerald Raverot, Laura De Marinis
Summary: This review provides an overview of the second-line therapies for acromegaly, summarizing the evidence on clinical, molecular, and morphological aspects that can predict the response to these treatments and advocating for a patient-tailored therapeutic approach in clinical practice.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Medicine, General & Internal
Alexandru Dan Popescu, Mara Carsote, Ana Valea, Andreea Gabriela Nicola, Ionela Teodora Dascalu, Tiberiu Tirca, Jaqueline Abdul-Razzak, Mihaela Jana Tuculina
Summary: Acromegaly-related sub/infertility is associated with suboptimal disease control, hyperprolactinemia, hypogonadotropic hypogonadism, and glucose profile anomalies. This review explores the impact of acromegaly on pregnancy outcomes and discusses management strategies. The level of disease control, family history of diabetes, and body mass index are important predictors of maternal complications. Pharmacotherapy has been shown to be safe and effective in improving pregnancy outcomes.
Article
Endocrinology & Metabolism
Thierry Brue, Philippe Chanson, Patrice Rodien, Brigitte Delemer, Delphine Drui, Lucile Marie, Laurene Juban, Lara Salvi, Robin Henocque, Gerald Raverot
Summary: The study aimed to estimate the cost-utility of second-line pharmacological treatments in acromegaly patients.
The incremental cost-utility ratios for pasireotide, pegvisomant, and pegvisomant + FGSA were estimated, showing pasireotide to be the least cost-efficient treatment option.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Laura E. Dichtel, Allison Kimball, Kevin C. J. Yuen, Whitney Woodmansee, Melanie S. Haines, Qiu Xia Guan, Brooke Swearingen, Lisa B. Nachtigall, Nicholas A. Tritos, Julie L. Sharpless, Ursula B. Kaiser, Anu V. Gerweck, Karen K. Miller
Summary: This study investigated the effects of growth hormone receptor antagonism versus somatostatin analog therapy on the quality of life in patients with acromegaly. The results showed that there were no significant differences in quality of life between patients receiving different treatment regimens, but higher HbA1c, BMI, and IGF-1 Z-scores were associated with poorer quality of life in several domains.
CLINICAL ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Andrea Giustina, Luigi di Filippo, Melin M. Uygur, Stefano Frara
Summary: A personalized approach to acromegaly treatment, utilizing novel clinical and molecular biomarkers, has shown promising results in predicting responsiveness to second-line medical treatments. Integrating these findings into existing guidelines may significantly improve the management of difficult acromegaly patients.
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonella Giampietro, Federica Mirra, Federico Donfrancesco, Tommaso Tartaglione, Pier Paolo Mattogno, Flavia Angelini, Lauretti Liverana, Marco Gessi, Anile Carmelo, Guido Rindi, Andrea Giustina, Maria Fleseriu, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi
Summary: The study investigated predictors of response to Pegvisomant and Pasireotide LAR in acromegaly patients, finding that factors such as tumor extension, Ki67-Li levels, and IGF-I levels may impact treatment efficacy.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Emmanuelle Kuhn, Philippe Caron, Brigitte Delemer, Isabelle Raingeard, Herve Lefebvre, Gerald Raverot, Christine Cortet-Rudelli, Rachel Desailloud, Clementine Geffroy, Robin Henocque, Yves Brault, Thierry Brue, Philippe Chanson
Summary: The study aimed to define the medical reasons for treating patients with Pegvisomant (PEG) as monotherapy or combined therapy with somatostatin analogs (SAs). Results showed different patterns of treatment based on patient characteristics and response to therapy, with a focus on tumor concern and ease of normalizing IGF-I levels. Overall, the prospect of reducing PEG injection frequency favored the choice of combined therapy in certain cases.
Article
Psychology, Clinical
Natalia Garcia-Casares, Marina Fernandez-Andujar, Inmaculada Gonzalez-Molero, Silvia Maraver-Selfa, Mario Gutierrez-Bedmar, Jose R. Ramos-Rodriguez, Francisco Alfaro-Rubio, Nuria Roe-Vellve, Isabel Garcia-Garcia, Juan A. Garcia-Arnes
Summary: This study did not find significant differences in cognitive function and brain cortical thickness between acromegaly patients treated with different medications. However, pegvisomant may have a neuroprotective role on the thalamus. Further research with larger samples is needed to confirm these findings.
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
(2021)
Review
Endocrinology & Metabolism
Monica R. Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuki
Summary: This article discusses the future perspectives of currently available SRLs, including the use of biomarkers of response and precision medicine, new formulations of these SRLs, and new drugs under development. Precision medicine based on biomarkers of response can help improve treatment decision-making and response rates. New formulations may improve patients' adherence to treatment and quality of life. New drugs may present higher efficacy than currently available drugs.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
E. Sala, G. Carosi, G. Del Sindaco, R. Mungari, A. Cremaschi, A. L. Serban, C. L. Ronchi, E. Ferrante, M. Arosio, G. Mantovani
Summary: A subset of well-controlled acromegalic patients can successfully withdraw from SAs, challenging the concept that medical therapy is a lifelong requirement.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2021)
Article
Medicine, General & Internal
Robert Pichler, Ognian Kalev, Berndt Tomancok, Michael Sonnberger, Daniela Ehrlich, Marina Hodolic
Summary: Somatostatin analogues, including first-generation analogues and pasireotide, are considered the first-line treatment for acromegaly, targeting different SSTR subtypes to improve therapeutic outcomes. Immunohistochemical analysis of SSTR subtypes may have predictive value for treatment response in patients with acromegaly, especially those with clinical relapse and complex clinical courses.
Review
Endocrinology & Metabolism
Manel Puig-Domingo, Ignacio Bernabeu, Antonio Pico, Betina Biagetti, Joan Gil, Cristina Alvarez-Escola, Mireia Jorda, Montserrat Marques-Pamies, Berta Soldevila, Maria-Angeles Galvez, Rosa Camara, Javier Aller, Cristina Lamas, Monica Marazuela
Summary: This paper proposes including the clinico-pathologic phenotype in the therapeutic algorithm for acromegaly, utilizing biomarkers for personalized medicine to accelerate the implementation of precision medicine. Additionally, the development, validation, and clinical use of a pasireotide acute test is suggested to identify patients responsive to pasireotide LAR.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Maria Fleseriu, Beverly M. K. Biller, Pamela U. Freda, Monica R. Gadelha, Andrea Giustina, Laurence Katznelson, Mark E. Molitch, Susan L. Samson, Christian J. Strasburger, A. J. van der Lely, Shlomo Melmed
Summary: This article focuses on recent advances in the management of acromegaly, emphasizing how key developments affect treatment decisions and outcomes. It also explores the potential role of recently FDA-approved therapies and combination therapies in the treatment arsenal.
Review
Endocrinology & Metabolism
Artak Labadzhyan, Shlomo Melmed
Summary: Molecular therapeutic targets in growth hormone-secreting adenomas have potential for drug development, including surface receptors recognized by approved drugs and markers for new drug candidates. Current medical therapies control the disease in most patients but the degree of control varies and is related to disease aggressiveness and tumor factors. Understanding the mechanisms behind these molecular markers and their relationship to outcomes holds promise for expanding treatment options and personalized approaches.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Monica R. Gadelha, Ana Carolina Gadelha, Leandro Kasuki
Summary: The treatment of acromegaly has advanced significantly in recent decades, but there are still patients who do not respond to current treatments, highlighting the need for improved treatment burden. Fortunately, there are new treatments in development that may enhance treatment efficacy and convenience.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Biochemistry & Molecular Biology
Nils B. Kroemer, Lena Krebs, Andrea Kobiella, Oliver Grimm, Maximilian Pilhatsch, Martin Bidlingmaier, Ulrich S. Zimmermann, Michael N. Smolka
Article
Endocrinology & Metabolism
Andrea Osswald, Evelyn Fischer, Christoph Degenhart, Marcus Quinkler, Martin Bidlingmaier, Anna Pallauf, Katharina Lang, Thomas Mussack, Klaus Hallfeldt, Felix Beuschlein, Martin Reincke
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2013)
Article
Cell Biology
Maximilian Bielohuby, Sarah Popp, Martin Bidlingmaier
GROWTH HORMONE & IGF RESEARCH
(2013)
Article
Psychiatry
Konstantina Apostolopoulou, Heike E. Kuenzel, Sabine Gerum, Katrin Merkle, Sebastian Schulz, Evelyn Fischer, Anna Pallauf, Volker Brand, Martin Bidlingmaier, Stephan Endres, Felix Beuschlein, Martin Reincke
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2014)
Article
Biochemistry & Molecular Biology
Andrea Osswald, Rong Wang, Felix Beuschlein, Michaela F. Hartmann, Stefan A. Wudy, Martin Bidlingmaier, Stephanie Zopp, Martin Reincke, Katrin Ritzel
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2019)
Review
Endocrinology & Metabolism
Jan M. Wit, Martin Bidlingmaier, Christiaan de Bruin, Wilma Oostdijk
JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY
(2020)
Article
Endocrinology & Metabolism
Uta Ferrari, Ralf Schmidmaier, Theresa Jung, Martin Reincke, Sebastian Martini, Benedikt Schoser, Martin Bidlingmaier, Michael Drey
Summary: The study analyzed the association of IGF-I, IGFBP3, and ALS with sarcopenia, finding that these factors were significantly reduced in sarcopenic patients. IGF-I and ALS were significantly associated with sarcopenia and low hand-grip strength, suggesting the presence of GH resistance.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Editorial Material
Endocrinology & Metabolism
Martin Bidlingmaier, Katharina Schilbach
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Arne Hinrichs, Simone Renner, Martin Bidlingmaier, John J. Kopchick, Eckhard Wolf
Summary: The study aimed to find possible explanations for the disappearance of juvenile hypoglycemia in GHRD patients and animal models. They found that in Israeli cohort, metabolic syndrome development was associated with decreasing insulin sensitivity, insulinopenia, and glucose intolerance, while in Ecuadorian patients and animal models insulin sensitivity was preserved or enhanced. The differences in glucose levels were not explained by alterations in food intake and energy consumption, nor was body fat accumulation associated with negative effects in both the Ecuadorian cohort and animal models.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Hanna Franziska Nowotny, Matthias K. Auer, Christian Lottspeich, Heinrich Schmidt, Ilja Dubinski, Martin Bidlingmaier, Jo Adaway, James Hawley, Brian Keevil, Nicole Reisch
Summary: The study found that adrenal 11oxC19 androgens exhibit a diurnal pattern in both patients and controls, with distinct peaks and declines throughout the day, being more pronounced in 21OHD patients. Compared to controls, the correlations between the corresponding steroids were weaker in patients, indicating that 11oxC19 steroids may be suitable for treatment monitoring in 21OHD patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Biochemistry & Molecular Biology
Matthias K. Auer, Luisa Paizoni, Meike Neuner, Christian Lottspeich, Heinrich Schmidt, Martin Bidlingmaier, James Hawley, Brian Keevil, Nicole Reisch
Summary: In patients with classic CAH, disturbances in the hypothalamus-pituitary-gonadal (HPG)-axis are common, with elevated 11-oxygenated androgens identified in women with menstrual disturbances and men with hypogonadotropic hypogonadism. However, it remains unclear if measuring 11-oxygenated androgens is more effective than conventional markers in assessing androgen control in these patients.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2021)
Article
Endocrinology & Metabolism
Ilja Dubinski, Susanne Bechtold, Martin Bidlingmaier, Nicole Reisch, Heinrich Schmidt
Summary: This study analyzed saliva samples from 22 patients with CAH to evaluate treatment response by measuring s17-OHP. The results showed that s17-OHP measurement is crucial for determining over-/undertreatment and assessing steroid requirements during changing phases. However, relying solely on s17-OHP is insufficient for distinguishing normal or abnormal growth or pubertal status.
HORMONE RESEARCH IN PAEDIATRICS
(2023)
Article
Endocrinology & Metabolism
Denise Bruedgam, Christian Adolf, Holger Schneider, Paul Schwarzlmueller, Lisa Mueller, Laura Handgriff, Martin Bidlingmaier, Sonja Kunz, Petra Zimmermann, Sinan Deniz, Tracy Ann Williams, Felix Beuschlein, Martin Reincke, Daniel A. Heinrich
Summary: This study aimed to investigate whether postoperative ACTH stimulated PAC can predict biochemical remission in patients with PA. The results showed that low postoperative ACTH stimulated PAC levels were predictive of biochemical remission.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Martin Bidlingmaier, Andre Valcour, Katharina Schilbach, Tim Kuehnle, Sven Diederich, Thomas Rogge, Etienne Cavalier, Alex Katayev
Summary: By comparing the IGF-I testing results from laboratories in the United States and Europe, it was found that the direct sampling and the indirect Hoffmann approach provided comparable reference intervals (RIs) in large datasets from the same population. Although the lower limits (LLs) were comparable between Europe and the United States, the upper limits (ULs) were significantly higher in the United States.
JOURNAL OF THE ENDOCRINE SOCIETY
(2022)
Review
Endocrinology & Metabolism
Katharina Schilbach, Martin Bidlingmaier
ARCHIVES OF ENDOCRINOLOGY METABOLISM
(2019)